Literature DB >> 10233850

Role of elevated plasma transforming growth factor-beta1 levels in wound healing.

M Shah1, D Revis, S Herrick, R Baillie, S Thorgeirson, M Ferguson, A Roberts.   

Abstract

Transforming growth factor (TGF)-beta1 plays a central role in wound healing. Wounds treated with neutralizing antibody to TGF-beta1 have a lower inflammatory response, reduced early extracellular matrix deposition, and reduced later cutaneous scarring, indicating the importance of local tissue TGF-beta1. By contrast, increasing the local, tissue levels of TGF-beta1 increases the early extracellular matrix deposition but does not alter scar formation. Increased levels of plasma TGF-beta1 correlate with increased fibrogenesis in the lung, kidneys, and liver. The aim of the present study was to investigate the role of elevated systemic levels of TGF-beta1 on wound healing. We used transgenic mice that express high levels of active TGF-beta1 and have elevated plasma levels of TGF-beta1 and wild-type mice of the same strain as controls. Incisional wounds and subcutaneously implanted polyvinyl alcohol (PVA) sponges were analyzed. Surprisingly, cutaneous wounds in transgenic, TGF-beta1-overexpressing mice healed with reduced scarring accompanied by an increase in the immunostaining for TGF-beta3 and TGF-beta-receptor RII and a decrease in immunostaining for TGF-beta1 compared with wounds in control mice. By contrast, the PVA sponges showed the opposite response, with PVA sponges from transgenic mice demonstrating an enhanced rate of cellular influx and matrix deposition into the sponges accompanied by an increase in the immunostaining for all three TGF-beta isoforms and their receptors compared with PVA sponges from control mice. Together, the data demonstrate that increased circulating levels of TGF-beta1 do not always result in increased expression or activity in selected target tissues such as the skin. The two wound models, subcutaneously implanted PVA sponges and cutaneous incisional wounds, differ significantly in terms of host response patterns. Finally, the data reinforce our previous observations that the relative ratios of the three TGF-beta isoforms is critical for control of scarring.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233850      PMCID: PMC1866570          DOI: 10.1016/s0002-9440(10)65364-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

Review 1.  Pathology of recombinant human transforming growth factor-beta 1 in rats and rabbits.

Authors:  T G Terrell; P K Working; C P Chow; J D Green
Journal:  Int Rev Exp Pathol       Date:  1993

Review 2.  Transforming growth factor-beta 1 and basic fibroblast growth factor in the injured CNS.

Authors:  A Logan; M Berry
Journal:  Trends Pharmacol Sci       Date:  1993-09       Impact factor: 14.819

3.  Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer.

Authors:  M S Anscher; W P Peters; H Reisenbichler; W P Petros; R L Jirtle
Journal:  N Engl J Med       Date:  1993-06-03       Impact factor: 91.245

4.  Regulation of expression of transforming growth factor-beta 2 by transforming growth factor-beta isoforms is dependent upon cell type.

Authors:  M A O'Reilly; D Danielpour; A B Roberts; M B Sporn
Journal:  Growth Factors       Date:  1992       Impact factor: 2.511

5.  One systemic administration of transforming growth factor-beta 1 reverses age- or glucocorticoid-impaired wound healing.

Authors:  L S Beck; L DeGuzman; W P Lee; Y Xu; M W Siegel; E P Amento
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

6.  Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities.

Authors:  R H Chen; R Ebner; R Derynck
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

7.  Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.

Authors:  T J Broekelmann; A H Limper; T V Colby; J A McDonald
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

8.  Complex regulation of TGF beta expression by retinoic acid in the vitamin A-deficient rat.

Authors:  A B Glick; B K McCune; N Abdulkarem; K C Flanders; J A Lumadue; J M Smith; M B Sporn
Journal:  Development       Date:  1991-04       Impact factor: 6.868

9.  Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents.

Authors:  M Shah; D M Foreman; M W Ferguson
Journal:  J Cell Sci       Date:  1994-05       Impact factor: 5.285

View more
  26 in total

Review 1.  The Use of Biologic Scaffolds in the Treatment of Chronic Nonhealing Wounds.

Authors:  Neill J Turner; Stephen F Badylak
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-08-01       Impact factor: 4.730

2.  Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.

Authors:  Anne-Charlotte de Gouville; Valerie Boullay; Gael Krysa; Julia Pilot; Jean-Marie Brusq; Florence Loriolle; Jean-Michel Gauthier; Stephen A Papworth; Alain Laroze; Françoise Gellibert; Stephane Huet
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

3.  Keloid skin scars: the influence of hyperbaric oxygenation on fibroblast growth and on the expression of messenger RNA for insulin like growth factor and for transforming growth factor.

Authors:  Mirza Romero-Valdovinos; Alexander Cárdenas-Mejía; Claudia Gutiérrez-Gómez; Ana Flisser; Simón Kawa-Karasik; Fernando Ortiz-Monasterio
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-05-14       Impact factor: 2.416

Review 4.  The evidence for the role of transforming growth factor-beta in the formation of abnormal scarring.

Authors:  Richard L Chalmers
Journal:  Int Wound J       Date:  2011-03-30       Impact factor: 3.315

5.  Early intervention with pulse dye and CO2 ablative fractional lasers to improve cutaneous scarring post-lumpectomy: a randomized controlled trial on the impact of intervention on final cosmesis.

Authors:  Tamar Safra; Waseem Shehadeh; Amir Koren; Fares Salameh; Or Friedman; Eli Sprecher; Ofir Artzi
Journal:  Lasers Med Sci       Date:  2019-04-26       Impact factor: 3.161

6.  TGF-β-responsive myeloid cells suppress type 2 immunity and emphysematous pathology after hookworm infection.

Authors:  Lisa Heitmann; Reena Rani; Lucas Dawson; Charles Perkins; Yanfen Yang; Jordan Downey; Christoph Hölscher; De'Broski R Herbert
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

7.  Activation of platelet-rich plasma using soluble type I collagen.

Authors:  Duretti Fufa; Blake Shealy; May Jacobson; Sherwin Kevy; Martha M Murray
Journal:  J Oral Maxillofac Surg       Date:  2008-04       Impact factor: 1.895

8.  Decreased collagen and increased matrix metalloproteinase-13 in experimental abdominal aortic aneurysms in males compared with females.

Authors:  Brenda S Cho; Karen J Roelofs; John W Ford; Peter K Henke; Gilbert R Upchurch
Journal:  Surgery       Date:  2009-09-20       Impact factor: 3.982

Review 9.  Wound-healing studies in transgenic and knockout mice.

Authors:  Richard Grose; Sabine Werner
Journal:  Mol Biotechnol       Date:  2004-10       Impact factor: 2.695

10.  Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression.

Authors:  Nguan Soon Tan; Liliane Michalik; Nicolas Di-Poï; Chuan Young Ng; Nicolas Mermod; Anita B Roberts; Béatrice Desvergne; Walter Wahli
Journal:  EMBO J       Date:  2004-10-07       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.